Characteristic | N | Unadjusted OR (95 % CI) | Age & gender adjusted OR (95 % CI) | Age, gender, smoking & obesity€ adjusted OR (95 % CI) |
---|---|---|---|---|
Age (per year) | 295 | 1.05 (1.03,1.07) | 1.05 (1.03,1.08) ₤ | 1.04 (1.02,1.07) ₤ |
Gender (Females vs. males) | 295 | 0.46 (0.23,0.92) | 0.43 (0.21,0.87) € | 0.37 (0.18,0.78) € |
BMI (per kg/m2) | 290 | 0.91 (0.85,0.97) | 0.93 (0.87,1.00) | 0.96 (0.86,1.07) |
Waist circumference (per inch) | 294 | 0.96(0.91,1.02) | 0.94(0.88,1.00) | 0.94 (0.88,1.00) |
Waist-hip ratio (per unit) | 294 | 1.11(0.77,1.60) | 0.72(0.45,1.16) | 0.92 (0.49,1.74) |
Cigarette use (Ever vs. never) | 295 | 1.01 (1.00,1.03) | 1.01 (0.99,1.03) | 0.99 (0.96,1.03) |
Pack-years continuous (per pack-year) | 295 | 1.01 (1.00,1.02) | 1.01 (1.00,1.02) | 1.01 (1.00,1.02) |
Pack-years Tertiles | - | |||
Non-smokers | REF | REF | REF | |
T1 (0.05-) | 0.58 (0.28,1.20) | 0.64 (0.30,1.35) | 0.64 (0.30,1.37) | |
T2 (14-) | 0.91 (0.47,1.76) | 0.79 (0.40,1.57) | 0.84 (0.42,1.70) | |
T3 (36-) | 1.58 (0.83,3.01) | 1.30 (0.66,2.56) | 1.40 (0.70,2.77) | |
p-trendb | 0.04** | 0.27 | 0.20 | |
Leptin (ng/ml) | 226 | 0.98 (0.95,1.01) | 1.00 (0.97,1.04) | 1.05 (1.01,1.12) |
Total Adiponectin (mcg/ml) | 226 | 1.08 (0.97,1.20) | 1.00 (0.88,1.15) | 0.98 (0.85,1.12) |
HMW Adiponectin (mcg/ml) | 226 | 1.10 (0.92,1.30) | 0.98 (0.79,1.21) | 0.92 (0.74,1.15) |
Glucose (mg/dL) | 226 | 0.99 (0.98,1.01) | 0.99 (0.97,1.01) | 0.99 (0.97,1.01) |
Insulin (uU/ml) | 226 | 1.00 (0.95,1.04) | 1.00 (0.95,1.05) | 1.02 (0.97,1.07) |
HOMA score | 226 | 0.95 (0.82,1.09) | 0.95 (0.81,1.12) | 1.01 (0.86,1.18) |
CRP continuous (mg/L) | 222 | 0.98 (0.87,1.11) | 0.95 (0.82,1.09) | 0.98 (0.84,1.13) |
CRP Tertiles | ||||
T1 (0.1-) | REF | REF | REF | |
T2 (1.1-) | 1.36 (0.67,2.74) | 1.40 (0.66,2.96) | 1.69 (0.78,3.68) | |
T3 (2.9-) | 0.91 (0.45,1.85) | 0.81 (0.37,1.78) | 1.04 (0.45,2.40) | |
p-trendb | 0.74 | 0.44 | 0.74 | |
IL-6 continuous (pg/ml) | 234 | 1.06 (0.95,1.17) | 1.02 (0.90,1.15) | 1.04 (0.92,1.18) |
IL-6 Tertiles | ||||
T1 (0.4-) | REF | REF | REF | |
T2 (1.5-) | 1.45 (0.74,2.86) | 1.21 (0.58,2.50) | 1.25 (0.59,2.62) | |
T3 (2.6-) | 1.25 (0.63-2.47) | 1.07 (0.50,2.31) | 1.22 (0.55,2.71) | |
p-trendb | 0.32 | 0.77 | 0.51 | |
sTNF-RI continuous (ng/ml) | 234 | 3.30 (1.75,6.23) | 2.02 (1.02,3.99) | 2.30 (1.11,4.78) |
sTNF-RI Tertiles | ||||
T1 (0.3-) | REF | REF | REF | |
T2 (1.2-) | 1.14 (0.56,2.33) | 0.90 (0.42,1.91) | 1.00 (0.46,2.15) | |
T3 (1.5-) | 3.25 (1.64,6.43) | 1.81 (0.85,3.84) | 2.19 (1.00,4.85) | |
p-trendb | <0.001** | 0.04** | 0.02 ** | |
sTNF-RII continuous (ng/ml) | 234 | 1.30 (1.07,1.58) | 1.08 (0.86,1.35) | 1.06 (0.84,1.33) |
sTNF-RII Tertiles | ||||
T1 (2.1-) | REF | REF | REF | |
T2 (4.9-) | 0.90 (0.44,1.82) | 0.64 (0.30,1.37) | 0.68 (0.32,1.47) | |
T3 (6.0-) | 2.52 (1.29,4.90) | 1.42 (0.66,3.04) | 1.45 (0.67,3.15) | |
p-trendb | 0.01** | 0.50 | 0.62 | |
F2-isoprostanes continuous (pg/ml) | 224 | 1.00 (0.99,1.01) | 1.00 (1.00,1.01) | 1.01 (1.00,1.02) |
F2-isoprostane Tertiles | ||||
T1 (14-) | REF | REF | REF | |
T2 (48-) | 0.62 (0.31,1.25) | 0.67 (0.32,1.41) | 0.72 (0.34,1.52) | |
T3 (67-) | 0.93 (0.48,1.83) | 1.28 (0.60,2.71) | 1.55 (0.71,3.39) | |
p-trendb | 0.88 | 0.31 | 0.18 |